Erdosteine is a homocysteine-derived thiol derivative. It is a N-acyl-amino acid with mucolytic and free radical scavenging properties. The two functional sulfhydryl groups in the molecule are released after the first-pass metabolism that turns Erdosteine into its pharmacologically active product Met-I.
The medication is recommended for the treatment of both chronic and acute respiratory diseases in over 40 countries across the globe. It is marketed under many brand names (Esteclin, Erdomed, Erdos, Erdotin, etc.) and is available in different formulations, including 300 mg hard capsules, 300 mg dispersible tablets, 225 mg granulates for oral suspension, and 175 mg/5ml powder for oral suspension.
|Name of Product||Erdosteine|
|IUPAC Name||2-[2-oxo-2-[(2-oxothiolan-3-yl)amino]ethyl]sulfanylacetic acid|
|Synonyms||Dithiosteine; Erdosteinum; Mucotec; Vectrine; Edirel; Erdotin; Erdosteína; Erdosteina|
|Molecular Weight||249.3 g/mol|
|2||Appearance (Color)||White to Beige|
|3||Solubility||Soluble in DMSO (≥ 20.0 mg/mL)|
Erdosteine is a pharmaceutical agent that is predominantly employed for its therapeutic effects in mucolysis and inflammation reduction. It is frequently recommended for a range of respiratory ailments, some of the major uses being as follows –
Some of the side effects associated with the use of Erdosteine are –
Q. What type of drug is Erdosteine?
Erdosteine is a medication that is derived from thiols and is categorized as a mucolytic agent.
Q. Is Erdosteine an antibiotic?
Erdosteine is not an antibiotic. It is an oral mucoactive anti-oxidant molecule, having synergistic action with antibiotic therapy in patients with acute infective exacerbation of chronic bronchitis.